Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 8/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.49 |
| ▸ | METAP1 | P53582 | 2/20 | 0.49 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 3/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175033 | 0.82 | CDK1 (0.69) | PDE5ANUDT1AURKACDK1CDK2 | |
| SCHEMBL30802417 | 0.82 | CDK1 (0.69) | PDE5ANUDT1AURKACDK1CDK2 | |
| SCHEMBL4094476 | 0.82 | CDK1 (0.69) | CDK1CDK2MKNK1MKNK2PDPK1 | |
| SCHEMBL27878086 | 0.75 | PDE5A (0.56) | PDE5ANUDT1AURKAMETAP1METAP2 | |
| SCHEMBL913494 | 0.75 | PDE5A (0.68) | PDE5ANUDT1AURKACDK1CDK2 | |
| SCHEMBL1170747 | 0.75 | METAP1 (0.72) | PDE5ANUDT1AURKAMETAP1METAP2 | |
| SCHEMBL1078302 | 0.74 | LRRK2 (0.52) | PDE5AAURKACDK1CDK2MKNK1 | |
| SCHEMBL4662719 | 0.72 | CLK2 (0.45) | CDK1CDK2MKNK1MKNK2PDPK1 | |
| SCHEMBL2386008 | 0.71 | NPC1 (0.56) | — | |
| SCHEMBL16432199 | 0.70 | KMT2A (0.52) | AURKAFGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454253-B1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GMBH (DE) | 2015-01-21 | — | — | EP | disclosed |
| EP-2454253-B1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GMBH (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| EP-2454253-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | Merck Patent GmbH (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006567-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | PDK1, PDK2, PDK4 | PDE5A 1040/4885NUDT1 3944/4885AURKA 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.